All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
During the 4th European CAR T-cell Meeting, the Multiple Myeloma Hub was pleased to speak with Michel Delforge, UZ Leuven, Leuven, BE. We asked, What are the future prospects and access to advanced immunotherapies for multiple myeloma (MM) in Europe?
Access and future prospects of advanced immunotherapies for multiple myeloma in Europe
In this video, Delforge explains the current treatment options for advanced refractory MM, comparing anti-BCMA CAR-T therapy with bispecific antibody therapy. Delforge also mentions both ciltacabtagene autoleucel (cilta-cel) and the CARTITUDE-1 trial (NCT03548207), and idecabtagene vicleucel (ide-cel) and the KarMMa trial (NCT03361748). Delforge highlights the importance of patient responses and overall survival rates, as well as considering the limited access to anti-BCMA CAR-T cells as an area of unmet patient need.
EHA2023 abstracts: What's hot in multiple myeloma and other plasma cell dyscrasias?
To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the...
My top 5 communications from the 18th IMW
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. He discussed the top five communications from the...
Subscribe to get the best content related to multiple myeloma delivered to your inbox